PEPG Stock Price & Analysis — Pepgen LTD (Healthcare >> Biotechnology)
PEPG FAQ
What is PEPG's ROE?
Pepgen LTD reports a Return on Equity (ROE) of -57.63%.
What is PEPG's dividend yield?
Pepgen LTD offers a dividend yield of 0.00%.
What is PEPG's Quality Score?
Our AI rates PEPG's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PEPG?
Our AI Timing Score for PEPG is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PEPG belong to?
Pepgen LTD is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
PEPG AI Analysis Summary
Our AI summary for PEPG: Pepgen LTD (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -57.63%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.88
Price
0.12
(6.82%)
Day Change
|
|
|---|
PEPG, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.12 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.88 |
| PBV / Sector |
0.91 / 44,219.29
GREAT
|
| Earning Per Share | -1.19 |
| PE / Sector |
N/A / 19.28
|
| PEG or PE/Growth / Sector |
N/A / 1.23
|
| Average 1M Daily Value |
2.47 M
GREAT
|
| Average 1W Daily Value |
0.93 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-04 08:01:59 |
| Symbol | PEPG |
| Name | PEPGEN LTD |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 69.17 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 121.74 / 9,645.64 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 321 Harrison Avenue, Boston, MA, United States, 02118
Phone: 781 797 0979
Website: https://www.pepgen.com
Employees: 59
Sector: Healthcare >> Biotechnology
Description: PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap
Google